Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
Shattuck Labs (NASDAQ: STTK) announced an upcoming oral presentation at the 20th Congress of ECCO in Inflammatory Bowel Diseases 2025, taking place in Berlin from February 19-22, 2025. The presentation will showcase results from IND-enabling toxicology studies of SL-325, their first-in-class DR3 blocking antibody, conducted in non-human primates.
Dr. Taylor Schreiber, CEO of Shattuck, will deliver the digital oral presentation titled 'Pre-Clinical Development of SL-325, a High Affinity DR3 Blocking Antibody, for Durable Blockade of the DR3/TL1A Axis in Inflammatory Bowel Disease' on February 20, 2025, at 6:15 PM CET. The presentation materials will be made available on the company's website after the event.
Shattuck Labs (NASDAQ: STTK) ha annunciato una prossima presentazione orale al 20° Congresso ECCO sulle Malattie Infiammatorie Intestinali 2025, che si terrà a Berlino dal 19 al 22 febbraio 2025. La presentazione mostrerà i risultati degli studi tossicologici abilitanti IND di SL-325, il loro anticorpo bloccante DR3 di prima classe, condotti su primati non umani.
Il Dr. Taylor Schreiber, CEO di Shattuck, presenterà digitalmente l'intervento intitolato 'Sviluppo Preclinico di SL-325, un Anticorpo Bloccante DR3 ad Alta Affinità, per il Blocco Duraturo dell'Asse DR3/TL1A nelle Malattie Infiammatorie Intestinali' il 20 febbraio 2025, alle 18:15 CET. I materiali della presentazione saranno resi disponibili sul sito web dell'azienda dopo l'evento.
Shattuck Labs (NASDAQ: STTK) anunció una próxima presentación oral en el 20º Congreso de ECCO sobre Enfermedades Inflamatorias Intestinales 2025, que se llevará a cabo en Berlín del 19 al 22 de febrero de 2025. La presentación mostrará los resultados de los estudios de toxicología habilitantes de IND de SL-325, su anticuerpo bloqueador DR3 de primera clase, realizados en primates no humanos.
El Dr. Taylor Schreiber, CEO de Shattuck, realizará la presentación oral digital titulada 'Desarrollo Preclínico de SL-325, un Anticuerpo Bloqueador DR3 de Alta Afinidad, para el Bloqueo Duradero del Eje DR3/TL1A en Enfermedad Inflamatoria Intestinal' el 20 de febrero de 2025, a las 18:15 CET. Los materiales de la presentación estarán disponibles en el sitio web de la empresa después del evento.
Shattuck Labs (NASDAQ: STTK)는 2025년 염증성 장 질환에 대한 제20회 ECCO Congress에서 구두 발표를 할 예정이며, 이 행사는 2025년 2월 19일부터 22일까지 베를린에서 개최됩니다. 발표는 SL-325의 IND 승인 독성 연구 결과를 비인간 영장류를 대상으로 진행한 내용을 보여줄 것입니다.
Shattuck의 CEO인 Taylor Schreiber 박사는 2025년 2월 20일 오후 6시 15분 CET에 '염증성 장 질환에서 DR3/TL1A 축의 지속적인 차단을 위한 고친화성 DR3 차단 항체 SL-325의 전임상 개발'이라는 제목의 디지털 구두 발표를 진행할 예정입니다. 발표 자료는 행사 후 회사 웹사이트에서 제공될 것입니다.
Shattuck Labs (NASDAQ: STTK) a annoncé une prochaine présentation orale lors du 20e Congrès de l'ECCO sur les Maladies Inflammatoires de l'Intestin 2025, qui se tiendra à Berlin du 19 au 22 février 2025. La présentation mettra en avant les résultats des études de toxicologie habilitantes IND de SL-325, leur anticorps bloquant DR3 de première classe, réalisées sur des primates non humains.
Le Dr. Taylor Schreiber, PDG de Shattuck, fera une présentation orale numérique intitulée 'Développement Préclinique de SL-325, un Anticorps Bloquant DR3 de Haute Affinité, pour le Blocage Durable de l'Axe DR3/TL1A dans les Maladies Inflammatoires de l'Intestin' le 20 février 2025 à 18h15 CET. Les matériaux de la présentation seront disponibles sur le site Web de l'entreprise après l'événement.
Shattuck Labs (NASDAQ: STTK) gab eine bevorstehende mündliche Präsentation auf dem 20. Kongress der ECCO zu entzündlichen Darmerkrankungen 2025 bekannt, der vom 19. bis 22. Februar 2025 in Berlin stattfinden wird. Die Präsentation wird die Ergebnisse von IND-erlaubenden Toxikologiestudien zu SL-325, ihrem erstklassigen DR3-blockierenden Antikörper, der an nichtmenschlichen Primaten durchgeführt wurde, präsentieren.
Dr. Taylor Schreiber, CEO von Shattuck, wird am 20. Februar 2025 um 18:15 Uhr MEZ die digitale mündliche Präsentation mit dem Titel 'Präklinische Entwicklung von SL-325, einem hochaffinen DR3-blockierenden Antikörper, für die dauerhafte Blockade der DR3/TL1A-Achse bei entzündlichen Darmerkrankungen' halten. Die Präsentationsmaterialien werden nach der Veranstaltung auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
AUSTIN, TX & DURHAM, NC, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced an upcoming oral presentation at the 20th Congress of ECCO in Inflammatory Bowel Diseases 2025 being held in Berlin, Germany from February 19–22, 2025. This presentation will feature results from the IND-enabling toxicology studies of SL-325, a first-in-class DR3 blocking antibody, in non-human primates.
Presentation Details:
- Title: Pre-Clinical Development of SL-325, a High Affinity DR3 Blocking Antibody, for Durable Blockade of the DR3/TL1A Axis in Inflammatory Bowel Disease
- Presenter: Dr. Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer
- Format: Digital oral presentation
- Session name: Session 4: Novel targets in IBD
- Date and Time: February 20, 2025; 6:15 PM – 6:21 PM CET
- Location: Session hall A5; CityCube Messe Berlin, Messedamm 26, 14055 Berlin, Germany
The presentation materials will be available on the Events and Presentations section of the Company’s website following the conclusion of the presentation.
About SL-325
SL-325 is a first-in-class Death Receptor 3 (DR3) antagonist antibody designed to achieve complete and durable blockade of the clinically validated TL1A/DR3 pathway. Shattuck’s preclinical studies demonstrate high affinity binding, superior efficacy over TL1A antibodies, and offer a data-driven rationale for targeting the TNF receptor, DR3, versus its ligand, TL1A. Shattuck expects to file an IND for SL-325 in the third quarter of 2025.
About Shattuck Labs, Inc.
Shattuck Labs, Inc. (Nasdaq: STTK) is a biotechnology company specializing in the development of potential treatments for autoimmune/inflammatory diseases. The Company is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory autoimmune diseases. Shattuck’s expertise in protein engineering and the development of novel TNF receptor agonist and antagonist therapeutics come together in its lead program, SL-325, a first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated TL1A/DR3 pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.
Investor & Media Contact:
Conor Richardson
Vice President of Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
FAQ
What will Shattuck Labs (STTK) present at ECCO 2025?
When and where will STTK present their SL-325 data at ECCO 2025?
What is the therapeutic target of STTK's SL-325 drug candidate?
Will STTK's ECCO 2025 presentation materials be publicly available?
